Business Sales

Business Sales NEW INSTRUCTION

Project Vitality

By Order of of the Proposed Joint Administrators

Location: National

Offers Invited: Immediately

KRE

BACKGROUND

KRE Corporate Recovery Limited are engaged to facilitate a sale of the business and assets of an established UK functional food and beverage brand operating in the fast-growing gut health and daily wellness category, whose products are sold through its own direct-to-consumer subscription platform, the principal online marketplaces, and a portfoliio of premium national health, grocery and specialist retail accounts.

KRE Corporate Recovery Limited are expected to be appointed as Joint Administrators shortly and will facilitate the sale via a pre-pack Administration.
 

BUSINESS OVERVIEW

  • Trading since 2023 in the fast-growing gut health and daily wellness category.
  • A proprietary functional drinks brand produced under an established contract-manufacturing arrangement.
  • Net sales of c.£223k in the 8m to August 2026.
  • Direct-to-consumer subscription is the largest channel, at just over half of 2026 sales year to date, with c.400 active subscribers.  DTC sales were £119k in the 8 months to August 2026, against £29k in the comparable prior-year period.
  • Product margin has risen to c.50% and gross margin after selling and distribution costs to 34%, following the recent switch to zero-rated VAT status.
  • A national listing with a major high-street health and wellbeing retailer, and a listing in a premium natural foods chain and halo trade accounts including members' clubs, corporate offices and specialist independents.
  • A core team of seven, supported by specialist agency partners for paid media, marketplace management and brand design.
  • Assets available include the brand and associated intellectual property, proprietary formulations, supplier and contract-manufacturer relationships, the customer and subscriber database, the e-commerce and marketing technology stack, retail listings and stock.
  • The business remains loss-making, having invested ahead of revenue in brand building and consumer acquisition, with an EBITDA loss of c.£850k in the 8m to August 2026.
     

 

NON DISCLOSURE AGREEMENT

If you would like more information about this company and to register your interest please complete and sign the attached non-disclosure agreement and return it to jhills@lsh.co.uk 

IMPORTANT

This briefing sheet contains information supplied by company personnel. LSH provides no warranties or indemnities in respect of such information. All interested parties must rely on their own investigations when reviewing this opportunity.

Get in touch